Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Dec 20;32(36):4174-5.
doi: 10.1200/JCO.2014.58.7006. Epub 2014 Nov 17.

Reply to N.-K.V. Cheung et al

Katherine K Matthay  1 , Wendy B London  2 , John Maris  3 , Peter C Adamson  3 , Julie R Park  4
Affiliations
Comment

Reply to N.-K.V. Cheung et al

Katherine K Matthay et al. J Clin Oncol. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST Disclosures provided by the authors are available with this article at www.jco.org. AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc. Katherine K. Matthay No relationship to disclose Wendy London Consulting or Advisory Role: United Therapeutics Corporation John M. Maris No relationship to disclose Peter C. Adamson Travel, Accommodations, Expenses: Pfizer Julie Park No relationship to disclose

Comment on

References

    1. Matthay KK, Reynolds CP, Seeger RC, et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children’s Oncology Group study. J Clin Oncol. 2009;27:1007–1013. - PMC - PubMed
    1. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis- retinoic acid. Children’s Cancer Group. N Engl J Med. 1999;341:1165–1173. - PubMed
    1. Cheung N-KV, Modak S, Ostrovnaya I, et al. When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care? J Clin Oncol. 2014;32:4173–4174. - PubMed
    1. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: A randomised controlled trial. Lancet Oncol. 2005;6:649–658. - PubMed
    1. Pritchard J, Cotterill SJ, Germond SM, et al. High dose melphalan in the treatment of advanced neuroblastoma: Results of a randomised trial (ENSG-1) by the European Neuroblastoma Study Group. Pediatr Blood Cancer. 2005;44:348–357. - PubMed

MeSH terms